Author

José Lázaro Pérez-Calle

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

José Lázaro Pérez-Calle  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

José Lázaro Pérez-Calle  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

José Lázaro Pérez-Calle  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

José Lázaro Pérez-Calle  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

José Lázaro Pérez-Calle  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

José Lázaro Pérez-Calle  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

José Lázaro Pérez-Calle  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

José Lázaro Pérez-Calle  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

José Lázaro Pérez-Calle  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

José Lázaro Pérez-Calle  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

José Lázaro Pérez-Calle  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

José Lázaro Pérez-Calle  et al.

Item 1 - 12 / 12
1